EP0245361A1 - Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties - Google Patents

Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties

Info

Publication number
EP0245361A1
EP0245361A1 EP19860906653 EP86906653A EP0245361A1 EP 0245361 A1 EP0245361 A1 EP 0245361A1 EP 19860906653 EP19860906653 EP 19860906653 EP 86906653 A EP86906653 A EP 86906653A EP 0245361 A1 EP0245361 A1 EP 0245361A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
amino
hydroxy
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19860906653
Other languages
German (de)
French (fr)
Inventor
Ruth E. Ten Brink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of EP0245361A1 publication Critical patent/EP0245361A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Definitions

  • the present Invention provides novel compounds. More particularly, the present invention provides novel renin-inhibiting peptide analogs. Most particularly, the present invention provides renin-inhibitory compounds having S-aryl-D- or L- or DL-cysteinyl, 3- (arylthio)lactic acid or 3- (arylthio)alkyl moieties at the 8 position (as compared to the renin substrate described below).
  • the renin inhibitors provided herein are useful for the diagnosis and control of renin-dependent hypertension.
  • Renin is an endopeptidase which specifically cleaves a particular peptide bond of its substrate (angiotensinogen), of which the N-terminal sequence in equine substrate is for example:
  • Renin cleaves angiotensinogen to produce angiotensin I, which is converted to the potent pressor angiotensin II.
  • a number of angiotensin I converting enzyme inhibitors are known to be useful in che treatment of hypertension.
  • Inhibitors of renin are also useful in the treatment of hypertension.
  • INFORMATION DISCLOSURE A number of renin-inhibitory peptides have been disclosed. Thus, U.S. patent 4,424,207, and European published applications 45,665 and 104,041 disclose certain peptides with the dipeptide at the 10,11-position containing an isostere bond.
  • statine derivatives stated to be renin inhibitors have been disclosed, see, e.g., European published applications 77,028; 81,783; and 114,993; and U.S. patents 4,478,826; 4,470,971 and 4,479,941.
  • Terminal disulfide cycles have also been disclosed in renin inhibiting peptides; see, e.g., U.S. patents 4,477,440 and 4,477,441.
  • Aromatic and aliphatic amino acid residues at the 10,11 position of the renin substrate are disclosed in U.S. patent 4,478,827.
  • C-terminal amide cycles are disclosed in U.S. patent 4,485,099.
  • the present invention particularly provides a renin inhibitory peptide of the formula X-A 6 -B 7 -C 8 -D 9 -E 10 -F 11 -G 12 -H 13 -I 14 -Z, wherein X is
  • D 9 is absent or a divalent moiety of the formula XL 3 or
  • R 18 or R 19 is hydroxy, mercapto, or amino, or a monosubstituted nitrogen containing group bonded through the nitrogen only when n is not one;
  • R 12 is -(CH 2 ) n -R 13 and n is zero and both R 13 and R 15 are oxygen-, nitrogen-, or sulfur-containing substituents bonded through the hetero atom, only when the hetero atom is not also bonded to hydrogen;
  • R 25 is -(CH 2 ) n -R 13 and n is zero only when R 13 is other than a primary or secondary nitrogen-containing group hydroxy or mercapto group or when R 4 of -N(R 4 )R 14 is other than hydrogen;
  • R 17 or R 19 is -COOH only when n for that moiety is other than zero;
  • R 16 or R 17 is an amino-containing substituent, hydroxy, mercapto, or -Het bonded through the hetero atom only when n for that substituent is an integer from two to five, inclusive;
  • R 13 and R 15 cannot both be -COOH; or a carboxy-, amino-, or other reactive group-protected form or a pharmaceutically acceptable acid addition salt thereof.
  • the present invention provides peptide inhibitors of renin which contain modification of the Phe 8 (angiotensinogen numbering) position. These modifications involve the insertion of a heteroatomcontaining fragment into the side chain of the residue occupying the Phe 8 position. These changes in the normal Phe side chain result in dramatic changes in the overall length and size of the side chain.
  • the hetero-atom also alters the polarity, angles, and H-bonding ability of the side chain elements. Additionally, changes in the backbone may be made such as substitution of oxygen for nitrogen in the corresponding ⁇ -amino acid.
  • Examples of pharmaceutically acceptable acid addition salts include: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate
  • the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix (C i C j ) indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive.
  • (C 1 -C 4 )alkyl refers to alkyl of one to 4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl, and isomeric forms thereof.
  • C 4 -C 7 cyclic amino indicates a monocyclic group containing one nitrogen and 4 to 7 carbon atoms.
  • Examples of (C 3 -C 1o )cycloalkyl which include alkyl-substituted cycloalkyl, are cyclopropyl, 2-methylcyclopropyl, 2, 2-dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, 2-methylcyclobutyl, 3-propylcyclobutyl, cyclopentyl, 2 , 2-dimethylcyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and isomeric forms thereof.
  • aryl examples include phenyl, naphthyl, (o-, m-, p-)tolyl, (o-, m-, p-)ethylphenyl, 2-ethyl-tolyl, 4-ethyl-o-tolyl, 5-ethyl-mtolyl, (o-, m-, or p-)propylphenyl, 2-propyl- (o-, m-, or p-)tolyl, 4isopropyl-2,6-xylyl, 3-propyl-4-ethylphenyl, (2,3,4- 2,3,6-, or 2,4,5-)trimethylphenyl, (o-, m-, or p-)fluorophenyl, (o-, m-, or p-trifluoromethyl)phenyl, 4-fluoro-2,5-xylyl, (2,4-, 2,5-, 2,6-, 3,4- , or 3,5-)
  • Examples of -Het include: 2-, 3-, or 4-pyridyl, imidazolyl, indolyl, N in - ormyl-indolyl, N in -C 2 -C 5 alkyl-C(O) -indolyl, [1,2,4]- triazolyl, 2-, 4-, or 5-pyrimidinyl, 2- or 3-thienyl, piperidinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyrazinyl, piperazinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolidinyl, isothiazolid
  • a heterocycle as defined herein for -Het would not be bonded through oxygen or sulfur or through nitrogen which is within a ring and part of a double bond.
  • Halo is halogen (fluoro, chloro, bromo, or iodo) or trifluoromethyl.
  • pharmaceutically acceptable cations include: pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations.
  • pharmacologically acceptable metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are also within the scope of this invention.
  • Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines.
  • novel peptides herein contain both natural and synthetic amino acid residues. These residues are depicted using standard amino acid abbreviations (see, e.g., Roberts, et al., Basic Principles of Organic Chemistry, pp. 703-705 (New York 1965)) unless otherwise indicated. All the renin-inhibiting compounds of the present invention may be administered in the conventional forms, such as disclosed in
  • the dosages of the present invention are for oral administration for treatment of humans to effect renin inhibition for the purpose of favorably affecting blood pressure.
  • the compounds are administered from 0.1 mg to 1000 mg per kg per dose, administered from 1 to 4 times daily. Equivalent dosages for other routes of administration are also employed.
  • the exact dose depends on the age, weight, and condition of the patient and on the frequency and route of administration. Such variations are within the skill of the practitioner or can readily be determined.
  • the compounds of the present invention may be pharmaceutically acceptable salts both those which can be produced from the free bases by methods well known in the art and those with which acids have pharmacologically acceptable conjugate bases.
  • the compounds of the present invention are preferably orally administered in the form of pharmacologically acceptable acid addition salts.
  • Preferred pharmacologically acceptable salts for oral administration include the citrate and aspartate salts, although any pharmacologically acceptable salt is useful in this invention, including those listed above. These salts may be in hydrated form.
  • the renin inhibiting polypeptides may be prepared by either polymer assisted or solution phase peptide synthetic procedures analogous to those described hereinafter or to those methods known in the art.
  • the carboxylic moiety of N ⁇ -t-butyloxycarbonyl (Boc)-substituted amino acid derivatives having suitable side chain protecting groups may be condensed with the amino functionality of a suitably protected amino acid, peptide or polymer-bound peptide using a conventional coupling protocol such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) in methylene chloride or dimethylformamide.
  • DCC dicyclohexylcarbodiimide
  • HOBT 1-hydroxybenzotriazole
  • N ⁇ Boc moiety may be selectively removed with 45% trifluoroacetic acid/2% anisole (v/v) in methylene chloride. Neutralization of the resultant trifluoroacetate salt may be accomplished with 10% diisopropylethylamine in methylenechloride.
  • this stepwise, coupling strategy may be partially or completely automated to provide the desired peptide-polymer intermediates. Anhydrous hydrofluoric acid treatment of the peptide-polymer intermediate may then be used to effect simultaneous protecting group removal and cleavage of the peptide from its polymeric support.
  • N in -formyl-indolyl-substituted peptides in which the N in -formyl-indolyl moiety Is stable to TFA or HF but may be removed by NH 3 or NaOH. Because FTrp is somewhat unstable to base in synthetic procedures, possibly causing lower yields, it may be desirable in solution phase synthesis to introduce the FTrp-contain ing moiety late in the synthetic sequence so that it is not exposed to such conditions.
  • N ⁇ n -formyl-Trp into compounds of the present invention is easily accomplished because of the commercial availability of N ⁇ -Boc-N in -formyl-Trp-OH.
  • the N in -formyl moiety may be introduced into indolyl-substituted amino acid derivatives or related compounds by reaction with HCl-formic acid as reported in the literature, see A. Previero et al, Biochim. BiophysActa 147, 453 (1967); Y.C.S. Yang et al, Int. J. Peptide Protein Res. 15, 130 (1980).
  • the compounds of the present invention may be in either free form or in protected form at one or more of the remaining (not previously protected) peptide, carboxyl, amino, hydroxy, or other reactive groups.
  • the protecting groups may be any of those known in the polypeptide art. Examples of nitrogen and oxygen protection groups are set forth in T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York, (1981); J.F.W. McOmie, ed. Protective Groups in Organic Chemistry, Plenum Press (1973); and J. Fuhrhop and G. Benzlin, Organic Synthesis, Verlag Chemie (1983).
  • nitrogen protective groups include t-butoxycarbonyl (Boc), benzyloxycarbonyl, acetyl, allyl, phthalyl, benzyl, benzoyl, trityl and the like.
  • Boc-(R.S)-3-(phenylthio)alanylHis-LeuY[CH(OH)CH 2 ]Val-IIe-2-(amldomethyl)pyridine is shown in Chart B.
  • Boc-IIe and 2-(aminomethyl)pyridine are coupled using DCC in CH 2 Cl 2 and aq. NaHCO 3 to give B-3.
  • BocLeuY[CH(OTBDMS)-CH 2 ]Val-OH is coupled to He-AMP (AMP-2- (amidomethy1)pyridine) using DEPC (diethyl cyanophosphonate) and Et 3 N in CH 2 Cl 2 to give B-4.
  • the Boc group of B-4 is removed with TFA and CH 2 Cl 2 and the resulting TFA salt is neutralized by extraction with CH 2 Cl 2 and aq. NaHCO 3 .
  • LeuY[CH(OTBDMS)-CH 2 ]Val-IIe-AMP is coupled with BocHis(Tos)-0H using DEPC and Et 3 N in C H2 Cl 2 to give B-5.
  • the Boc group and tert-butyldimethylsilyl group of B-7 are removed with TFA and CH 2 Cl 2 .
  • the resulting TFA salt is neutralized via extraction with CH 2 Cl 2 and aq. NaHCO 3 to give B-6.
  • Compound B-6 is coupled with Boc(R,S)-3-(phenylthio)alanine using DCC in CH 2 Cl 2 .
  • the tosyl protecting group on the histidine side chain is removed with l-HOBT and MeOH to give the final product, B-7.
  • the mercaptide anion of cycloalkyl-SH or alkyl-SH (formed from , for instance, the commercially available mercaptan and NaOMe or NaH) is added to A-3 and carried through the sequences of Charts A and B to give compounds such as A-5 and B-7 in which cycloalkyl-S- and alkyl-S-replace arylS-.
  • Chart E outlines the synthesis of intermediates for the preparation of compounds of this invention wherein X is R 6 -(CH 2 ) i -C(O) -from known (commercially available) halo ester E-1 or halo ester E-3.
  • Halo ester E-1 is reacted with the mercaptide anion of R 6 SH to give thio ether E-2, which is hydrolyzed to give acid E-S.
  • halo acid E-3 is converted to a salt such as the sodium salt E-4 which is reacted with the anion of R 6 SH followed by acidification to give acid E-5.
  • E-5 may be incorporated into peptides of this invention, e.g., D-5.
  • DMF dimethylformamide
  • MsCl methanesulfonyl chloride
  • Et 3 N triethylamine
  • CH 2 Cl 2 methylene chloride
  • MeOH methanol
  • TFA trifluoroacetic acid
  • DEPC diethylcyanophosphonate
  • 1-HOBT 1-hydroxybenzotriazole
  • TBDMS tert-butyldimethylsilyl
  • Tos is p-toluenesulfonyl
  • His(Tos) is histidyl protected on the imidazole nitrogen with Tos,
  • THF is tetrahydrofuran
  • AMP is (2-pyridinyl)methylamino
  • DCC is dicyclohexylcarbodiimide
  • NaHCO 3 is sodium bicarbonate
  • Na 2 SO 4 is sodium sulfate.
  • Mass spec m/z at 297 (theory , 297) .
  • Chart B (B-1 + B- 2 to B- 3) .
  • Boc-IIe-AMP (1.60 g, 4.98 mmoles) and 50% TFA-CH 2 Cl 2 (20 ml) is stirred for 30 minutes, after which TFA and CH 2 Cl 2 are removed in vacuo. The residue is exhustively extracted with CH 2 Cl 2 and aq. NaHCO 3 . The organic layers are filtered through Na 2 SO 4 and taken to dryness.
  • reaction is extracted with CHCl 3 and aq. NaHCO 3 and the organic layers are filtered through Na 2 SO 4 and concentrated. CH 2 Cl 2 and hexane are added to the residue and, after cooling in the refrigerator, the solvent is decanted. The remaining solid is stirred for 40 hours with 0.031 g of 1-HOBT in 30 ml of MeOH and 5 ml of CH 2 Cl 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nouveaux peptides inhibiteurs de rénine ayant comme formule X-A6-B5-C8-D9-E10-F11-G12-H13-I14-Z, où X et Z sont des groupes terminaux, C8 contient S-aryl-D-cystéinyle ou L-cystéinyle ou DL-cystéinyle, de l'acide 3-(arylthio)lactique et des moitiés de 3-(arylthio)alkyle, les variables restantes étant des résidus d'acides aminés. Ces inhibiteurs sont utiles pour le diagnostic et la régulation de l'hypertension dépendant de la rénine.New renin inhibitor peptides having the formula X-A6-B5-C8-D9-E10-F11-G12-H13-I14-Z, where X and Z are terminal groups, C8 contains S-aryl-D-cysteinyl or L -cysteinyl or DL-cysteinyl, 3- (arylthio) lactic acid and 3- (arylthio) alkyl halves, the remaining variables being amino acid residues. These inhibitors are useful for the diagnosis and regulation of renin-dependent hypertension.

Description

NOVEL RENIN INHIBITING POLYPEPTIDE ANALOGS CONTAINING S-ARYL-D- OR L- OR DL-CYSTEINYL, 3- (ARYLTHIO)LACTIC ACID OR 3-(ARYLTHIO)ALKYL MOIETIES DESCRIPTION BACKGROUND OF THE INVENTION
The present Invention provides novel compounds. More particularly, the present invention provides novel renin-inhibiting peptide analogs. Most particularly, the present invention provides renin-inhibitory compounds having S-aryl-D- or L- or DL-cysteinyl, 3- (arylthio)lactic acid or 3- (arylthio)alkyl moieties at the 8 position (as compared to the renin substrate described below). The renin inhibitors provided herein are useful for the diagnosis and control of renin-dependent hypertension.
Renin is an endopeptidase which specifically cleaves a particular peptide bond of its substrate (angiotensinogen), of which the N-terminal sequence in equine substrate is for example:
Renin ↓
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser- IA 1 2 3 4 5 6 7 8 9 10 11 12 13 14
as found by L.T. Skeggs et al, J. Exper. Med. 106, 439 (1957). Human renin substrate has a different sequence as recently discovered by D.A. Tewkesbury et al, Biochem. Biophys. Res. Comm. 99, 1311 (1981). It may be represented as follows: Renin ↓
-Val-Ile-His-
11 12 13 IB
and having the sequence to the left of the arrow (↓)) being as designated in formula IA above.
Renin cleaves angiotensinogen to produce angiotensin I, which is converted to the potent pressor angiotensin II. A number of angiotensin I converting enzyme inhibitors are known to be useful in che treatment of hypertension. Inhibitors of renin are also useful in the treatment of hypertension. INFORMATION DISCLOSURE A number of renin-inhibitory peptides have been disclosed. Thus, U.S. patent 4,424,207, and European published applications 45,665 and 104,041 disclose certain peptides with the dipeptide at the 10,11-position containing an isostere bond. A number of statine derivatives stated to be renin inhibitors have been disclosed, see, e.g., European published applications 77,028; 81,783; and 114,993; and U.S. patents 4,478,826; 4,470,971 and 4,479,941. Terminal disulfide cycles have also been disclosed in renin inhibiting peptides; see, e.g., U.S. patents 4,477,440 and 4,477,441. Aromatic and aliphatic amino acid residues at the 10,11 position of the renin substrate are disclosed in U.S. patent 4,478,827. C-terminal amide cycles are disclosed in U.S. patent 4,485,099. Certain tetrapeptides are disclosed in European publications 111,266 and 77,027. Further, European published application No. 118,223 discloses certain renin inhibiting peptide analogs where the 10-11 peptide link is replaced by a one to four atom carbon or carbon-nitrogen link. Additionally, Holladay et al., in "Synthesis of Hydroxyethylene and Ketomethylene Dipeptide Isosteres", Tetrahedron Letters, Vol. 24, No. 41, pp. 4401-4404, 1983 disclose various intermediates in a process to prepare stereo-directed "ketomethylene" and "hydroxyethylene" dipeptide isosteric functional groups disclosed in the above noted U.S. Patent No. 4,424,207.
Additionally, published European Applications 45,161 and 53,017 disclose amide derivatives useful as inhibitors of angiotensin converting enzymes.
SUMMARY OF THE INVENTION The present invention particularly provides a renin inhibitory peptide of the formula X-A6-B7-C8-D9-E10-F11-G12-H13-I14-Z, wherein X is
(a) hydrogen,
(b) Cχ-C5alkyl
(c) R5-O-CH2-C(O)-,
(d) R5-CH2-O-C(O)-, (e) R5-O-C(O)-,
(f) R5-(CH2)n-C(O)-,
(g) R4N(R4)-(CH2)n-C(O), (h) R5-SO2-(CH2)q-C(O)-, (i) R5-SO2-(CH2)q-O-C(O)-, or (j) R6-(CH2)i-C(O)-; wherein A6 is absent or a divalent moiety of the formula XI1, XL2, or XL2a wherein B7 is absent or a divalent moiety of the formula XIb wherein C8 is absent or a divalent moiety of the formula XL1 or
wherein D9 is absent or a divalent moiety of the formula XL3 or
XL2a , wherein E10-F11 is a divalent moiety of the formula XL6, XL6a,
XL6b , X L6c ' XL6 d or XL6e, wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G12 is absent or a divalent moiety of the formula XL4 or XL4a wherein H13 is absent or a divalent moiety of the formula XL4 wherein I14 is absent or a divalent moiety of the formula XL5 wherein Z is
(a) -O-R10,
(b) -N(R4)R14, or
(c) C4-C8 cyclic amino; wherein R is
(a) isopropyl,
(b) isobutyl,
(c) phenylmethyl, or
(d) C3-C7 cycloalkyl; wherein R1 is
(a) hydrogen,
(b) C1-C5 alkyl,
(c) aryl,
(d) C3-C7 cycloalkyl,
(e) -Het,
(f) C1-C3 alkoxy, or
(g) C1-C3alkylthio; wherein R2 is
(a) hydrogen, or
(b) -CH(R3)R4; wherein R3 is (a) hydrogen,
(b) hydroxy,
(c) C1-C5 alkyl,
(d) C3-C7 cycloalkyl,
(e) aryl,
(f) -Het,
(g) C1-C3 alkoxy, or (h) C1-C3 alkylthio; wherein R4 at each occurrence is
(a) hydrogen, or
(b) C1-C5alkyl; wherein R5 is
(a) C1-C6alkyl,
(b) C3- C7 cycloalkyl,
(c) aryl,
(d) -Het, or
(e) 5-oxo-2-pyrrolidinyl; wherein R6 is
(a) -S-aryl,
(b ) -S-C3-C7 cycloalkyl, or
(c ) -S-C1-C6alkyl; wherein R7 is
(a ) hydrogen,
(b ) C1-C5 alkyl,
(c ) hydroxy,
(d ) amino C1-C4 alkyl-,
(e) guanidinyl C1-C3 alkyl-,
(f ) aryl,
(g ) -Het,
(h ) methylthio,
(i ) C3-C7 cycloalkyl, or
(j) amino; wherein R8 is
(a ) hydrogen,
(b ) C1-C5 alkyl,
(c) hydroxy,
(d ) aryl,
(e) -Het, (f) guanidinyl C1-C3 alkyl-, or
(g) C3-C7 cycloalkyl; wherein Rg is
(a) hydrogen,
(b) hydroxy,
(c) amino C1-C4 alkyl-, or
(d) guanidinyl C1-C3 alkyl-; wherein R10 is
(a) hydrogen,
(b) C1-C5 alkyl,
(c) -(CH2)nR16,
(d) -(CH2)nR17,
(e) C3-C7 cycloalkyl,
(f) a pharmaceutically acceptable cation,
(s) -(CHR25)-CH2-R15, or (h) -CH2 - (CHR12 ) -R15 ; wherein R 11 is -R or -R2; wherein R 12 is - (CH2)n-R13 ; wherein R 13 is
(a) aryl,
(b) amino,
(c) mono-, di or tri-C1-C3 alkylamino,
(d) -Het,
(e) C1-C5 alkyl
(f) C3 -C7 cycloalkyl,
(g) Cχ-C5alkenyl,
(h) C3 -C7 cycloalkeny1,
(i) hydroxy,
(j) C1 -C3 alkoxy,
(k) C1 -C3 alkanoyloxy,
(I) mercapto,
(m) C1-C3alkylthio,
(n) -COOH,
(o) -CO-O-C1-C6 alkyl,
(P) -CO-O-CH2 - (C1 -C3 alkyl)-N(C1 -C3 alkyl)2 ,
(q) -CO-NR22R26;
(r) C4-C7 cyclic amino,
(s) C4-C7 cycloalkylamino, (t) guanidyl,
(u) cyano,
(v) N-cyanoguanidyl,
(w) cyano amino ,
(x) (hydroxy C2 -C4 alkyl) amino, or
(y) di-(hydroxy C2-C4 alkyl) amino; wherein R14 is
(a) hydrogen,
(b) C1-C10 alkyl,
(c) - (CH2-)n-R18 ,
(d:) - (CH2)n-R19 ,
(e) -(CHR25)-CH2-R15,
(f) - CH2-(CHR12) -R15 ,
(g) (hydroxy C1-C8 alkyl), or
(h) (C1-C3alkoxy)C1-C8 alkyl; wherein R15 is
(a) hydroxy,
(b) C3-C7 cycloalkyl ,
(c) aryl,
(d) amino,
(e) mono-, di-, or tri- C1 -C3 alkylamino,
(f) mono- or di- [hydroxy C2 -C4 alkyl] amino,
(g) -Het,
(h) C1-C3alkoxy-,
(i) C1-C3 alkanoyloxy-,
(j ) mercapto,
(k) C1-C3alkylthio-,
(I) C1-C5 alkyl,
(m) C4-C7cyclic amino,
(n) C4- C7 cycloalkylamino,
(o) C1- C5 alkenyloxy,
(P) C3 - C7 cycloalkenyl; wherein R16 is
(a) aryl,
(b) amino,
(c) mono- or di- C1-C3 alkylamino,
(d) hydroxy,
(e) C3-C7 cycloalkyl, (f) C4-C7 cyclic amino, or
(g) C1-C3 alkanoyloxy; wherein R17 is
(a) -Het, (b) C1-C5alkenyl,
(c) C3 -C7cycloalkenyl,
(d) C1-C3alkoxy,
(e) mercapto,
(f) C1-C3alkylthio, (g) -COOH,
(h) -CO-O-C1-C6alkyl,
(i) -CO-O-CH2-(C1-C3 alkyl)-N(C1-C3alkyl)2,
(j) -CO-NR22R25,
(k) tri-C1-C3 alkylamino, (1) guanidyl,
(m) cyano,
(n) N-cyanoguanidyl,
(0) (hydroxy C2-C4 alkyl)amino, or (p) di- (hydroxy C2 -C4 alkyl) amino; wherein R18 is
(a) amino,
(b) mono-, or di- C1 -C3 alkylamino, or
(c) C4-C7 cyclic amino; wherein R19 is (a) aryl,
(b) -Het,
(c) tri-C1-C3 alkylamino,
(d) C3-C7 cycloalkyl,
(e) C1-C5 alkenyl, (f) C3-C7 cycloalkenyl,
(g) hydroxy,
(h) C1-C3 alkoxy,
(i) C1-C3 alkanoyloxy,
(j) mercapto, (k) C1-C3 alkylthio,
(1) -COOH,
(m) -CO-O-C1-C6alkyl,
(n) -CO-O-CH2-(C1-C3 alkyl)-N(C1-C3alkyl)2, (o) -CO-NR22R26,
(P) C4-C7 cycloalkylamino,
(q) guanidyl,
(r) cyano,
(s) N-cyanoguanidyl,
(t) cyanoamino,
(u) (hydroxy C2-C4 alkyl) amino,
(v) di-(hydroxy C2 -C4 alkyl)amino; or
(w) -SO3H; wherein R20 is
(a) hydrogen,
(b) C1-C5 alkyl, or
(c) aryl-C1-C5alkyl; wherein R21 is
(a) -NH2, or
(b) -OH; wherein R 22 is
(a) hydrogen, or
(b) C1-C3 alkyl; wherein R 23 is
(a) -(CH2)n-OH,
(b) -(CH2)n-NH2,
(c) aryl, or
(d) C1-C3 alkyl; wherein R 24 is
(a) -R1,
(b) -(CH2)n-OH, or
(c) -(CH2)n-NH2; wherein R25 is -(CH2)n-R13; wherein R26 is
(a) hydrogen,
(b) C1-C3 alkyl, or
(c) phenyl-C1-C3 alkyl; wherein i is one to three, inclusive; wherein m is one or two; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to 2 inclusive; wherein q is 1 to 5, inclusive; wherein Q is
(a) -CH2-, (b) -CH(OH)-, (c) -O-, or
(d) -S-; and wherein M is
(a) -CO-, or
(b) -CH2-; wherein aryl is phenyl or naphthyl substituted by zero to 3 to the following:
(a) Cχ-C3 alkyl,
(b) hydroxy,
(c) C1-C3alkoxy,
(d) halo,
(e) amino,
(f) mono- or di-C1-C3 alkylamino,
(g) -CHO, (h) -COOH,
(i) COOR26, (j) CONHP26 , (k) nitro,
(I) mercapto, (m) C1-C3 alkylthio, (n) C1-C3 alkylsulfinyl, (o) C1-C3 alkylsulfonyl, (P) -N(R4)-C1-C3 alkylsulfonyl,
(q) SO3H,
(r) SO2NH2, (s) -CN, or
(t) -CH2NH2; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicvclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following:
(i) C1-C6 alkyl, (ii) hydroxy, (iii) trifluoromethyl, (iv) C1-C4alkoxy, (v) halo, (vi) aryl,
(vii) aryl C1-C4 alkyl-, (viii) amino, and
(ix) mono- or di-C1-C4 alkylamino; with the overall provisos that (1) X is R6-(CH2)i-C(O)- only when A6, B7, and C8 are absent;
(2) R18 or R19 is hydroxy, mercapto, or amino, or a monosubstituted nitrogen containing group bonded through the nitrogen only when n is not one;
(3) R12 is -(CH2)n-R13 and n is zero and both R13 and R15 are oxygen-, nitrogen-, or sulfur-containing substituents bonded through the hetero atom, only when the hetero atom is not also bonded to hydrogen;
(4) R25 is -(CH2)n-R13 and n is zero only when R13 is other than a primary or secondary nitrogen-containing group hydroxy or mercapto group or when R4 of -N(R4)R14 is other than hydrogen; and
(5) R17 or R19 is -COOH only when n for that moiety is other than zero;
(6) R16 or R17 is an amino-containing substituent, hydroxy, mercapto, or -Het bonded through the hetero atom only when n for that substituent is an integer from two to five, inclusive; and
(7) when R12 is -(CH2)n-R13 and n is zero, then R13 and R15 cannot both be -COOH; or a carboxy-, amino-, or other reactive group-protected form or a pharmaceutically acceptable acid addition salt thereof. These compounds are shown in relation to the human renin substrate as follows:
6 7 8 9 10 11 12 13 -His Pro Phe His Leu Val He His- X As B7 C8 D9 E1o F11 G12 H13 I14 Z, The present invention provides peptide inhibitors of renin which contain modification of the Phe8 (angiotensinogen numbering) position. These modifications involve the insertion of a heteroatomcontaining fragment into the side chain of the residue occupying the Phe8 position. These changes in the normal Phe side chain result in dramatic changes in the overall length and size of the side chain. The hetero-atom also alters the polarity, angles, and H-bonding ability of the side chain elements. Additionally, changes in the backbone may be made such as substitution of oxygen for nitrogen in the corresponding α-amino acid. These changes, in addition to being chemically novel to renin inhibitors, also confer stability to the position 8-9 bond to the action of chymotrypsin and elastase due to the lack of fit of the lengthened side chain into the active site pocket of these enzymes.
Examples of pharmaceutically acceptable acid addition salts include: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix (CiCj) indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus (C1-C4)alkyl refers to alkyl of one to 4 carbon atoms, inclusive, or methyl, ethyl, propyl, butyl, and isomeric forms thereof. C4-C7 cyclic amino indicates a monocyclic group containing one nitrogen and 4 to 7 carbon atoms.
Examples of (C3-C1o)cycloalkyl which include alkyl-substituted cycloalkyl, are cyclopropyl, 2-methylcyclopropyl, 2, 2-dimethylcyclopropyl, 2,3-diethylcyclopropyl, 2-butylcyclopropyl, cyclobutyl, 2-methylcyclobutyl, 3-propylcyclobutyl, cyclopentyl, 2 , 2-dimethylcyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl and isomeric forms thereof. Examples of aryl include phenyl, naphthyl, (o-, m-, p-)tolyl, (o-, m-, p-)ethylphenyl, 2-ethyl-tolyl, 4-ethyl-o-tolyl, 5-ethyl-mtolyl, (o-, m-, or p-)propylphenyl, 2-propyl- (o-, m-, or p-)tolyl, 4isopropyl-2,6-xylyl, 3-propyl-4-ethylphenyl, (2,3,4- 2,3,6-, or 2,4,5-)trimethylphenyl, (o-, m-, or p-)fluorophenyl, (o-, m-, or p-trifluoromethyl)phenyl, 4-fluoro-2,5-xylyl, (2,4-, 2,5-, 2,6-, 3,4- , or 3,5-)difluorophenyl, (o-, m-, or p- )chloropheny1, 2-chloro-ptolyl, (3-, 4-, 5- or 6-)chloro-o-tolyl, 4-chloro-2-propylphenyl, 2- isopropyl-4-chlorophenyl, 4-chloro-3-fluorophenyl, (3- or 4-)chloro2-fluorophenyl, (o-, m-, or p-)trifluoro-methylphenyl, (o-, m-, or p-)ethoxyphenyl, (4- or 5-)chloro-2-methoxy-phenyl, and 2,4-dichloro(5- or 6-)methylphenyl.
Examples of -Het include: 2-, 3-, or 4-pyridyl, imidazolyl, indolyl, Nin- ormyl-indolyl, Nin-C2 -C5alkyl-C(O) -indolyl, [1,2,4]- triazolyl, 2-, 4-, or 5-pyrimidinyl, 2- or 3-thienyl, piperidinyl, pyrryl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyrazinyl, piperazinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl, and benzothienyl. Each of these moieties may be substituted as noted above.
As would be generally recognized by those skilled in the art of organic chemistry, a heterocycle as defined herein for -Het would not be bonded through oxygen or sulfur or through nitrogen which is within a ring and part of a double bond.
Halo is halogen (fluoro, chloro, bromo, or iodo) or trifluoromethyl. Examples of pharmaceutically acceptable cations include: pharmacologically acceptable metal cations, ammonium, amine cations, or quaternary ammonium cations. Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminum, zinc, and iron are also within the scope of this invention. Pharmacologically acceptable amine cations are those derived from primary, secondary, or tertiary amines.
The novel peptides herein contain both natural and synthetic amino acid residues. These residues are depicted using standard amino acid abbreviations (see, e.g., Roberts, et al., Basic Principles of Organic Chemistry, pp. 703-705 (New York 1965)) unless otherwise indicated. All the renin-inhibiting compounds of the present invention may be administered in the conventional forms, such as disclosed in
U.S. Patent No. 4,424,207 which Is incorporated by reference herein.
Likewise, the amounts disclosed in the U.S. Patent No. 4,424,207 are examples applicable to the compounds of the present invention.
Preferably, the dosages of the present invention are for oral administration for treatment of humans to effect renin inhibition for the purpose of favorably affecting blood pressure. For this purpose, the compounds are administered from 0.1 mg to 1000 mg per kg per dose, administered from 1 to 4 times daily. Equivalent dosages for other routes of administration are also employed.
The exact dose depends on the age, weight, and condition of the patient and on the frequency and route of administration. Such variations are within the skill of the practitioner or can readily be determined.
The compounds of the present invention may be pharmaceutically acceptable salts both those which can be produced from the free bases by methods well known in the art and those with which acids have pharmacologically acceptable conjugate bases. The compounds of the present invention are preferably orally administered in the form of pharmacologically acceptable acid addition salts. Preferred pharmacologically acceptable salts for oral administration include the citrate and aspartate salts, although any pharmacologically acceptable salt is useful in this invention, including those listed above. These salts may be in hydrated form.
The compounds of the present invention are prepared as depicted in the charts and as described more fully in the Preparations and Examples.
The description below refers to the structures depicted on the formula page and in the Charts A-E. In those formulas, all variables are as defined above except where noted.
Generally, the renin inhibiting polypeptides may be prepared by either polymer assisted or solution phase peptide synthetic procedures analogous to those described hereinafter or to those methods known in the art. For example, the carboxylic moiety of Nα-t-butyloxycarbonyl (Boc)-substituted amino acid derivatives having suitable side chain protecting groups, if necessary, may be condensed with the amino functionality of a suitably protected amino acid, peptide or polymer-bound peptide using a conventional coupling protocol such as dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBT) in methylene chloride or dimethylformamide. The synthetic procedures used to incorporate the novel moieties herein are also described, for example, in U.S. patents 4,424,207; 4,470,971; 4,477,440; 4,477,441; 4,478,826; 4,478,827; 4,479,941; and 4,485,099, and copending application Serial No. 753,198, filed 9 July 1985, all of which are expressly incorporated by reference herein. See, also, published European patent applications 45,161; 45,665; 53,017; 77,028; 77,029; 81,783; 104,041; 111,266; 114,993; and 118,223.
Following coupling reaction completion, the Nα Boc moiety may be selectively removed with 45% trifluoroacetic acid/2% anisole (v/v) in methylene chloride. Neutralization of the resultant trifluoroacetate salt may be accomplished with 10% diisopropylethylamine in methylenechloride. In the case of polymer-assisted peptide synthesis, this stepwise, coupling strategy may be partially or completely automated to provide the desired peptide-polymer intermediates. Anhydrous hydrofluoric acid treatment of the peptide-polymer intermediate may then be used to effect simultaneous protecting group removal and cleavage of the peptide from its polymeric support. A notable exception to this includes Nin-formyl-indolyl-substituted peptides in which the Nin-formyl-indolyl moiety Is stable to TFA or HF but may be removed by NH3 or NaOH. Because FTrp is somewhat unstable to base in synthetic procedures, possibly causing lower yields, it may be desirable in solution phase synthesis to introduce the FTrp-contain ing moiety late in the synthetic sequence so that it is not exposed to such conditions.
The incorporation of Nιn -formyl-Trp into compounds of the present invention is easily accomplished because of the commercial availability of Nα-Boc-Nin-formyl-Trp-OH. However, the Nin -formyl moiety may be introduced into indolyl-substituted amino acid derivatives or related compounds by reaction with HCl-formic acid as reported in the literature, see A. Previero et al, Biochim. BiophysActa 147, 453 (1967); Y.C.S. Yang et al, Int. J. Peptide Protein Res. 15, 130 (1980).
Generally, methods of alkylation useful in alkylating histidine for use in the present invention are found in Cheung, S.T. et al, Can. J. Chem., Vol 55, pp. 906-910 (1977). However it is now found that in Cheung, S. T. et al, methods it is critical that the reaction conditions for the alkylation of histidine be anhydrous. Further, it is now found also that during work-up instead of adding water directly to the reaction mixture, it is preferred that a buffered aqueous solution be added to the reaction mixture, for example, aqueous sodium or potassium hydrogen sulfate.
This is analogous to that found in Cheung, S.T. et al, Can. J. Chem. Vol 55, pp. 906-910 (1977)), however, it has been found that the process requires anhydrous reaction conditions which are not taught by Cheung et al.
Variations in the above description for starting materials, reactants, reaction conditions and required protecting groups to obtain other such N-alkylated compounds are known to an ordinarily skilled chemist or are readily available in the literature. These peptides may also be prepared by the standard solid phase techniques of Merrifield. Appropriate protecting groups, reagents, and solvents for both the solution and solid phase methods can be found in "The Peptides: Analysis, Synthesis, and Biology," Vols. 1-5, eds. E. Gross and T. Meienhofer, Academic Press, NY, 1979-1983.
The compounds of the present invention may be in either free form or in protected form at one or more of the remaining (not previously protected) peptide, carboxyl, amino, hydroxy, or other reactive groups. The protecting groups may be any of those known in the polypeptide art. Examples of nitrogen and oxygen protection groups are set forth in T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York, (1981); J.F.W. McOmie, ed. Protective Groups in Organic Chemistry, Plenum Press (1973); and J. Fuhrhop and G. Benzlin, Organic Synthesis, Verlag Chemie (1983). Included among the nitrogen protective groups are t-butoxycarbonyl (Boc), benzyloxycarbonyl, acetyl, allyl, phthalyl, benzyl, benzoyl, trityl and the like.
In general, the processes of the present invention may be carried out in the following manner. The synthesis of the key intermediate, Boc- (R,S)-3-(phenylthio)alanine, is shown in Chart A. This synthesis follows the method of G. Glynn and D. Beight, Tet. Lett.; 25:2655 (1984). Boc-Serine (Boc-D,L-Ser may be used as chirality is lost at a later step) is converted to its methyl ester using a five-fold excess of methyl iodide and two equivalents of NaHCO3 in DMF as solvent. The alcohol (A-2) is then converted to the mesylate with methanesulfonyl chloride and 1 equiv. of Et3N in CH2Cl2. Addition of a second equivalent of Et3N gives the elimination product A-3. Compound A- 3 is stirred with 1.1 equivalents of thiophenol and a catalytic amount of Et3N in MeOH to give A-4. Hydrolysis of the methyl ester with aq. NaOH in MeOH, followed by acidification, gives Boc-(R,S)-3-(phenylthio)alanine A-5. The peptides are synthesized by methods known to the art. See, for instance, the series "The Peptides: Analysis, Synthesis, Biology, Vols. 1-5, eds. E. Gross and J. Meienhofer, Academic Press, New York, 1979-1983. The assembly of Boc-(R.S)-3-(phenylthio)alanylHis-LeuY[CH(OH)CH2]Val-IIe-2-(amldomethyl)pyridine is shown in Chart B. Boc-IIe and 2-(aminomethyl)pyridine (both commercially available) are coupled using DCC in CH2Cl2 and aq. NaHCO3 to give B-3. BocLeuY[CH(OTBDMS)-CH2]Val-OH is coupled to He-AMP (AMP-2- (amidomethy1)pyridine) using DEPC (diethyl cyanophosphonate) and Et3N in CH2Cl2 to give B-4. The Boc group of B-4 is removed with TFA and CH2Cl2 and the resulting TFA salt is neutralized by extraction with CH2Cl2 and aq. NaHCO3. LeuY[CH(OTBDMS)-CH2 ]Val-IIe-AMP is coupled with BocHis(Tos)-0H using DEPC and Et3N in CH2Cl2 to give B-5. The Boc group and tert-butyldimethylsilyl group of B-7 are removed with TFA and CH2Cl2. The resulting TFA salt is neutralized via extraction with CH2Cl2 and aq. NaHCO3 to give B-6. Compound B-6 is coupled with Boc(R,S)-3-(phenylthio)alanine using DCC in CH2Cl2. The tosyl protecting group on the histidine side chain is removed with l-HOBT and MeOH to give the final product, B-7. In a similar manner, the mercaptide anion of cycloalkyl-SH or alkyl-SH (formed from , for instance, the commercially available mercaptan and NaOMe or NaH) is added to A-3 and carried through the sequences of Charts A and B to give compounds such as A-5 and B-7 in which cycloalkyl-S- and alkyl-S-replace arylS-.
The syntheses of key intermediates C-4A and C-5 are shown in Chart C. Commercial L-malic acid is converted to the halide C-2 via the method of Larcheveque and Petit, Tet. Letters, 25:3705 (1984) and references cited therein. Reaction of C-2 with thiophenoxide anion (generated from thiophenol and base) gives ester C-3. Ester C-3 is hydrolyz®ed with aqueous NaOH in MeOH, followed by acidification, to give acid C-3A. Acid C-3A is converted to the O-acetate with Ac2O in pyridine to give C-4A. Coupling of C-3A with His(Tos)-Leu¥[CH(OH)CH2]Val-IIe-AMP using DEPC and Et3N in CH2Cl2, followed by removal of the tosyl group with l-HOBT, gives C-5A. Compound C-3 is converted to the carbamate derivate C-4 with diethyl carbamoyl chloride, NaH, Et3N, and THF. Compound C-4 is hydrolyzed to the acid with aqueous NaOH in MeOH, followed by acidification. Coupling of C-5 with His(Tos)-Leu¥[CH(OH)CH2]Val-IIe-AMP using DEPC and Et3N in CH2Cl2, followed by removal of the tosyl group with l-HOBT in MeOH, gives C-6. In a similar manner, ther mercaptide anions, cycloalkylS- and alkyl-S- (from the mercaptan and a base such as NaOMe and NaH), may be added to C-2 and carried through the above sequence to give compounds of the general structures C-5A and C-6 with cycloalkyl-S- and alkyl-S- replacing aryl-S-. The synthesis of D-5 is outlined in Chart D. Reaction of thiophenoxide anion with ethyl acrylate gives ester D-2. Hydrolysis of D-2 with aqueous NaOH and MeOH, followed by acidification, gives acid D-3. Coupling of D-3 with His(Tos)-Leu¥[CH(OH)CH2]Val-IIe-AMP using DEPC and Et3N in CH2Cl2, followed by removal of the tosyl group with 1-HOBT in MeOH, gives D-5.
Chart E outlines the synthesis of intermediates for the preparation of compounds of this invention wherein X is R6-(CH2)i-C(O) -from known (commercially available) halo ester E-1 or halo ester E-3. Halo ester E-1 is reacted with the mercaptide anion of R6SH to give thio ether E-2, which is hydrolyzed to give acid E-S. Alternatively halo acid E-3 is converted to a salt such as the sodium salt E-4 which is reacted with the anion of R6SH followed by acidification to give acid E-5. In the same manner as the conversion of D-3 to D-5, E-5 may be incorporated into peptides of this invention, e.g., D-5. DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following Preparations and Examples illustrate the present invention.
In the Preparations and Examples below and throughout this document: DMF is dimethylformamide, MsCl is methanesulfonyl chloride, Et3N is triethylamine, CH2Cl2 is methylene chloride, MeOH is methanol, TFA is trifluoroacetic acid, DEPC is diethylcyanophosphonate, 1-HOBT is 1-hydroxybenzotriazole, TBDMS is tert-butyldimethylsilyl, Tos is p-toluenesulfonyl,
His(Tos) is histidyl protected on the imidazole nitrogen with Tos,
Ac2O is acetic anhydride, pyr is pyridine,
THF is tetrahydrofuran, AMP is (2-pyridinyl)methylamino, DCC is dicyclohexylcarbodiimide, NaHCO3 is sodium bicarbonate, and Na2SO4 is sodium sulfate. Preparation 1 Boc-Serine Methyl Ester Chart A (A-1 to A-2).
A mixture of 2.05 g (0.010 moles) of Boc-L-Ser, 3.27 ml (0.050 moles) in Mel, 1.68 g (0.020 moles) of NaHCO3 , and 25 ml of DMF is stirred overnight at room temperature. DMF is removed in vacuo and the residue is extracted with EtOAc, H2O, and brine. The organic layers are filtered through Na2SO4, concentrated, and chromatographed on silica gel using 2% MeOH-CH2Cl2 to give 2.03 g (93%) of titled product.
TLC (4% MeOH-CH2Cl2): Rf is 0.41. 1H-NMR (CDC13): 8 1.45, s, 9H; 2.52, t, 1 H; 3.78, s, 3H; 3.91, m, 2H; 4.30, m, 1 H; 5.45, bd, 1 H.
Preparation 2 Boc-(R,S)-3-(Phenylthio)alanine Methyl Ester Chart A (A-2 to A-3 to A-4).
To Boc-Ser-OCH3 (0.099 g, 0.451 mmoles) and Et3N (0.069 ml, 0.497 mmoles) in 3 ml of CH2Cl2 at 0° is added 0.038 ml (0.497 mmoles) of methanesulfonyl chloride. After 2 1/3 hours, an additional 0.07 ml (0.5 mmoles) of Et3N is added and the ice bath is removed. After stirring an additional 1 2/3 hours, the reaction mixture is extracted with CH2Cl2, H2O, and brine. The organic layers are filtered through Na2SO4, concentrated and chromatographed on silica gel to give 0.0723 g (80%) of methylene intermediate A-3 (Rf is 0.61, 20% EtOAc-hexane).
A solution of 0.0723 g (0.358 mmoles) of the methylene intermediate, 0.043 g (0.393 mmoles) of thiophenol, 4 drops of Et3N, and 15 ml of MeOH is stirred overnight. MeOH is then removed in vacuo and the residue kept under high vacuum for several hours to give 0.1096 g (98%) of titled product.
TLC (20% EtOAc-hexane): Rf is 0.38. 1H-NMR (CDCl3): δ 1.41, s, 9 H; 3.36, d, 2H; 3.54, s, 3 H; 4.50, m, 1 H; 5.25, bd, 1H; 7.3, m, 5H. Preparation 3 Boc-(R,S)-3-(Phenylthio)alanine
Chart A (A-4 to A-5)
To a solution of 0.100 g (0.321 mmoles) of the ester of Preparation 2 in 3-4 ml of MeOH is added dropwise 0.48 ml of 1 N NaOH (exotherm). After stirring for 1 hour, MeOH is removed in vacuo and the residue is extracted with CH2Cl2 and 2N NCI. The organic layers are filtered through Na2SO4 and taken to dryness in vacuo to give 0.0828 g (87%) of product. Crystallization from CH2Cl2-hexane gives 0.07 g of product, mp. 104-106°.
TLC (4% MeOH-CH2Cl2-HOAc): Rf is 0.30.
Mass spec : m/z at 297 (theory , 297) .
Calcd for C1 4 H1 9NO4 S : C , 56 .54 ; H, 6 .44 ; N, 4. 71. Found: C , 56 .40 ; H, 6 .58 ; N , 4.60. 1H-NMR (CDCl3 ) : δ 1.42 , s ; 1. 35 , m; 1.4 , m; 5.45 , bd; 7 .3 , m.
Preparation 5 Boc-Ile-AMP
Chart B (B-1 + B- 2 to B- 3) .
To 3.15 g (0.0136 moles) of Boc-He and 2.08 g (0.0136 moles) of l-HOBT in 50 ml of CH2Cl2 is added 1.34 g (0.0123 moles) of 2-(aminomethyl)pyridine. After 5-10 minutes, 2.81 g (0.0136 moles) of DCC is added. After 35 minutes, DCU is filtered off and the filtrate is washed with aqueous NaHCO3. The organic layers are filtered through Na2SO4, concentrated, re-filtered to remove DCU, and chromatographed on silica gel using 4% MeOH/CH2Cl2 to give 3.94 g (100%) of product. The solid is crystallized from EtOAc/hexane to give the titled product: 2.28 g of a first crop, m.p. 102-103.5° C, and 1.50 g of second and third crops.
Calcd. for C17N27N3O3: C, 63.52; H, 8.47; N, 13.07. Found: C, 63.37; H, 8.55; N, 12.86. 1H-NMR (CDCI3): δ 0.89-0.97, m; 1.43, s, Boc; 1.76, s; 4.0, m, α-CH; 4.56, d (J-5.1), CH2Py; 5.05, d, NH; 7.0-8.5, m, aromatic. Preparation 6 Boc-Leu¥[CH(OH)CH2 ]Val-Ile-AMP
B-3 to B-4. Boc-IIe-AMP (1.60 g, 4.98 mmoles) and 50% TFA-CH2Cl2 (20 ml) is stirred for 30 minutes, after which TFA and CH2Cl2 are removed in vacuo. The residue is exhustively extracted with CH2Cl2 and aq. NaHCO3. The organic layers are filtered through Na2 SO4 and taken to dryness.
To a solution of 0.0509 g (0.114 mmoles) of Boc-Leu¥[CH(OTBDMS)CH2]Val-OH, 0.0253 (0.114 mmoles) of Ile-AMP, and 0.0154 g (0.114 mmoles) of 1-HOBT in 3 ml of CH2Cl2 is added 0.0235 g (0.114 mmoles) of DCC. After stirring over the weekend (reaction over much sooner), DCU is filtered off and the filtrate is extracted with CH2Cl2 and aq NaHCO3. The organic layers are filtered through Na2SO4, concentrated, and the crude product is chromatographed on silica gel using 3% MeOH-CH2Cl2 (NH4OH sat'd) to give 0.0630 g (85%) of product. TLC (4% MeOH-CH2Cl2): Rf is 0.14. 1H-NMR (CDCl3): 8 0.11, s; 0.90, s; 0.83-0.95, m; 1.43, s; 3.1, m; 4.5, m; 6.10, bd; 7.1-7.8, m; 9.03, bd. Preparation 7 Boc-His(Tos)-Leu¥[CH(OTBDMS)CH2 ]Val-Ile-AMP B-4 t B-5.
A solution of 0.063 g (0.097 mmoles) of B-4 from Preparation 6 in 5 ml of TFA-CH2Cl2 (1:1) is stirred for 15 minutes at room temperature and then concentrated in vacuo. The residue is extracted with CH2C12 and aq. NaHCO3 and the organic layers are filtered through Na2SO4 and concentrated to dryness. To this is added Boc¬
His(Tos)-OH (0.06 g, 0.146 mmoles) and 4 ml of CH2Cl2 , followed by 0.030 g (0.146 mmoles) of DCC. After stirring 2.5 hours at room temperature, DCU is filtered off and the filtrate is concentrated.
EtOAc is added and DCU is filtered off again. The filtrate is concentrated and the residue is chromatographed on silica gel using
2% MeOH-CH2Cl2→4% MeOH-CH2Cl2 (NH4OH sat'd) to give 0.0793 g (87%) of the titled product.
1HNMR (CDCl3): δ 0.07, s; 0.88-0.95, m; 1.40, s; 2.42, s; 5.95, bd; 6.20, bd; 6.65, bd; 7.05-8.5, m.
TLC (4% MeOH-CH2Cl2-NH4OH sat'd): Rf is 0.38. Preparation 8 His(Tos)-Leu¥[CH(OH)CH2 ]Val-Ile-AMP B-5 to B-6.
A solution of 0.079 g (0.084 mmoles) of B-5 from Preparation 7 in 10 ml of TFA-CH2C12 (1:1) is stirred for 4 hours at room temperature. TFA and CH2Cl2 are then removed in vacuo and the residue is extracted with CH2Cl2 and aq NaHCO3. The organic layers are filtered through Na2SO4 and concentrated. The crude product is chromatographed on silica gel (10 g) using 6% MeOH-CH2Cl2 (NH4OH sat'd) to give 0.0513 g (84%) of the titled product. TLC (8% MeOH-CH2Cl2-NH4OH): Rf is 0.40.
Example 1 Boc-((S-phenyl)-DL-Cys)-His-Leu¥[CH(OH)CH2 ]Val-He-AMP B-6 to B-7.
To 0.0056 g (0.0187 mmoles) of Boc- (R,S) -3(phenylthio)alanine (A-5 from Preparation 3) and 0.0091 g (0.0125 mmoles) of B-6 from Preparation 8 in 3 ml of CH2Cl2 is added 0.0039 g (0.0187 mmoles) of DCC . After stirring for 30 minutes, the reaction mixture is chromatographed on silica gel (10 g) using 6% MeOH-CH2Cl2 (NH4OH sat'd) to give 12.7 mg of the (impure) Tos-protected titled product (Rf is 0.42 in 8% MeOH-CH2Cl2-NH4OH). This Tos-protected material is stirred for 2 days with 0.02 g of l-HOBT in 1 ml of MeOH, after which MeOH is removed in vacuo. The residue is chromatographed on silica gel (10 g) using 6% MeOH-CH2Cl2 (NH4OH sat'd) to give 0.0077 g of the titled product.
TLC (6% MeOH-CH2Cl2-NH4OH): Rf is 0.11. FAB mass spec: [M+H] at m/z 851 (cald'd 851).
1-NMR (CDC13) for the Tos-protected titled product: δ 1.40, s; 1.43, s (Boc group of each isomer); 2.42 bs (tosyl CH3 ).
HPLC: Brownlee C18 column, phosphate pH 3 buffer: 50% A-50% B, k' is 8.3 (broad), 94.3% purity; flow rate 1.5 ml/min, A 0.1,225 nM. Preparation 9 Ethyl 3-(Phenylthio)propionate
A solution of 0.203 g (1.84 mmoles) of thiophenol, 0.182 g (1.82 mmoles) of ethyl acrylate, 5 drops of Et3N, and 5 ml of EtOH was stirred at room temperature for 3 hours. The mixture is then taken to dryness in vacuo to give 0.372 g of product (clear liquid). TLC (10% EtOAc-hexane) : Rf is 0.44. 1H-NMR (CDCl3): 5 1.24, t, 3 H; 2.60, complex t 2 H; 3.16, complex t, 2 H; 4.14, q, 2H; 7.3, m, 5H. Preparation 10 3-(Phenylthio)propionic acid
To a solution of 0.143 g (0.68 mmoles) of ethyl 3-(phenylthio)propionate in 5 ml of MeOH is added dropwise 0.816 ml (0.816 mmoles) of 1 N NaOH. After 35 minutes, MeOH is removed in vacuo and the aqueous residue is extracted with hexane and H2O. The hexane layer is removed and discarded and the aqueous layer is acidified with 0.27 ml of 3 N HCl. The aqueous mixture is extracted with EtOAc (backwashed with brine) and organic layers are filtered through Na2SO4 and taken to dryness in vacuo to give 0.1044 g (84%) of product. Crystallization from EtOAc-hexane gives (1st and 2nd crops) 0.066 g of the titled product, m.p. 59.5-60.0°.
TLC (20% EtOAc-hexane): slight movement off baseline. Mass spec.: m/z at 182.
Calc'd for CgH10O2S: C, 59.31; H, 5.53. Found: C, 59.02; H, 5.51. 1H-NMR (CDCl3): 8 2.66, complex t, 2H; 3.16, complex t, 2H; 7.3, m, 5H.
Example 2 3-(Phenylthio)propionyl-His-Leu¥[CH(OH)CH2]Val-Ile-AMP
A mixture of 0.0139 g (0.0763 mmoles) of 3-(phenylthio)propionic acid, 0.0503 g (0.0694 mmoles) of His(Tos)-Leu¥[CH(OH)CH2 ]Val-IIeAMP, 0.0126 ml (0.0832 mmoles) of DEPC, 0.0116 ml (0.0832 mmoles) of
Et3N, and 3 ml of CH2Cl2 is stirred at room temperature for 2 hours.
The reaction is extracted with CHCl3 and aq. NaHCO3 and the organic layers are filtered through Na2SO4 and concentrated. CH2Cl2 and hexane are added to the residue and, after cooling in the refrigerator, the solvent is decanted. The remaining solid is stirred for 40 hours with 0.031 g of 1-HOBT in 30 ml of MeOH and 5 ml of CH2Cl2.
The solvents are then removed in vacuo and extraction with CHCL3-aq.¬
NaHCO3 is attempted. This results in a bad precipitation of product
(mostly suspended in the aqueous phase). The CHCl3 layer is removed and the aqueous suspension is centrifuged and decanted. The pellet is centrifuged twice with H2O and the remaining solid is absorbed onto silica gel and chromatographed on silica gel (10 g) using 8%
MeOH-CH2Cl2 (NH4OH sat'd) to give 0.0352 g of the titled compound.
TLC (8% MeOH-CH2Cl2-NH4OH): Rf is 0.16. FAB mass spec: [M+H] measured: 736.4211; theory: 736.4220.
HPLC: pH 3 phosphate buffer, Brownlee C18 column: 60% A-40% B, k' is 5.8, 100% purity; 225 nM, A 0.1, flow rate 1.5 ml/min. Example 3 (Phenylthio)acetyl-His-Leu¥[CH(OH)CH2]Val-Ile-AMP
Using methods described herein, the titled compound is prepared. FAB mass spec: [M+H] measured: 722.404;
722.4063.

Claims

CLAIMS 1. A renin inhibitory peptide of the formula X-A6-B7-C8-D9-E1-
O-F11-G12-H13-I14-Z, wherein X is
(a) hydrogen,
(b) C1-C5 alkyl
(c) R5-O-CH2-C(O)-,
(d) R3-CH2-O-C(O)-,
(e) R5-O-C(O)-,
(f) R5-(CH2)n-C(O)-,
(g) R4N(R4)-(CH2)n-C(O), (h) R5-SO2-(CH2)q-C(O)-,
(i) R5-SO2-(CH2)q-O-C(O), or (j) R6-(CH2)i-C(O)-; wherein A6 is absent or a divalent moiety of the formula XL1, XL2, or XL2a
wherein B7 is absent or a divalent moiety of the formula XLb
τ wherein C8 is absent or a divalent moiety of the formula XL1 or
XL2 ,
, wherein D9 is absent or a divalent moiety of the formula XL3 or
XL2a,
wherein E10-F11 is a divalent moiety of the formula XL6, XL6a, XL6b, XL6C, XL6d, or XL6a ,
wherein * indicates an asymmetric center which is either in the R or S configuration; wherein G12 is absent or a divalent moiety of the formula XL4 or
XL 4a ,
wherein H13 is absent or a divalent moiety of the formula XL4 α
wherein I14 is absent or a divalent moiety of the formula XL5
wherein Z is
(a) -O-R10,
(b) -N(R4)R14, or
(c) C4-C8 cyclic amino; wherein R is
(a) isopropyl,
(b) isobutyl,
(c) phenylmethyl, or
(d) C3-C7 cycloalkyl; wherein R1 is
(a) hydrogen,
(b) C1-C5 alkyl,
(c) aryl,
(d) C3-C7 cycloalkyl,
(e) -Het,
(f) C1-C3 alkoxy, or (g) C1-C3alkylthio; wherein R2 is
(a) hydrogen, or
(b) -CH(R3)R4; wherein R3 is
(a) hydrogen,
(b) hydroxy,
(c) C1-C5 alkyl,
(d) C3 -C7 cycloalkyl,
(e) aryl,
(f) -Het,
(g) C1-C3alkoxy, or
(h) C1-C3alkylthio; wherein R4 at each occurrence is the same or different and is
(a) hydrogen, or
(b) C1-C5 alkyl; wherein R5 is
(a) C1-C6 alkyl,
(b) C3-C7 cycloalkyl,
(c) aryl,
(d) -Het, or
(e) 5-oxo-2-pyrrolidiny1; wherein R6 is
(a) -S-aryl,
(b) -S-C3-C7 cycloalkyl, or
(c) -S-C1-C6 alkyl; wherein R7 is
(a) hydrogen,
(b) C1-C5 alkyl,
(c) hydroxy,
(d) amino C1-C4 alkyl-,
(e) guanidinyl C1-C3 alkyl-,
(f) aryl,
(g) -Het,
(h) methylthio,
(i) C3-C7 cycloalkyl, or
(j) amino; wherein R8 is (a) hydrogen,
(b) C1-C5 alkyl,
(c) hydroxy,
(d) aryl,
(e) -Het,
(f) guanidinyl C1-C3 alkyl-, or
(g) C3 -C7 cycloalkyl; wherein R9 is
(a) hydrogen,
(b) hydroxy,
(c) amino C1-C4 alkyl-, or
(d) guanidinyl C1-C3 alkyl-; wherein R10 is
(a) hydrogen,
(b) C1-C5 alkyl,
(c) -(CH2)nR16,
(d) -(CH2)nR17 ,
(e) C3 -C7 cycloalkyl,
(f) a pharmaceutically acceptable cation,
(g) -(CHR25)-CH2-R15, or
(h) -CH2 - (CHR12) -R15; wherein R11 is -R or -R2; wherein R12 is - (CH2)n -R13 ; wherein R13 is
(a) aryl,
(b) amino,
(c) mono-, di or tri-C1-C3 alkylamino,
(d) -Het,
(e) C1-C5 alkyl
(f) C3 -C7 cycloalkyl, (g) C1 -C5 alkenyl,
(h) C3-C7 cycloalkenyl,
(i) hydroxy,
(j) C1-C3 alkoxy,
(k) C1-C3 alkanoyloxy,
(l) mercapto,
(m) C1-C3 alkylthio,
(n) -COOH, (o) -CO-O-C1-C6 alkyl, (P) -CO-O-CH2 - (C1 -C3 alkyl) -N(C1 -C3 alkyl)2 , (q) -CO-NR22R26; (r) C4-C7 cyclic amino, (s) C4- C7 cycloalkylamino, (t) guanidyl, (u) cyano, (v) N-cyanoguanidyl, (w) cyano amino , (x) (hydroxy C2-C4 alkyl)amino, or
(y) di- (hydroxyC2-C4 alkyl)amino ; wherein R14 is (a) hydrogen, (b) C1-C10 alkyl, (c) - (CH2)n- R18 , (d) -(CH2)n-R19 , (e) -(CHR25 )-CH2-R15, (f) -CH2-(CHR12)-R15, (g) (hydroxy C1-C8alkyl), or (h) (C1-C3 alkoxy)C1-C8 alkyl ; wherein R15 is (a) hydroxy, (b) C3-C7 cycloalkyl, (c) aryl, (d) amino, (e) mono-, di-, or tri- C1-C3 alkylamino, (f) mono- or di-[hydroxy C2-C4alkyl]amino,
(g) -Het, (h) C1-C3 alkoxy-,
(i) C1-C3 alkanoyloxy-, (j) mercapto, (k) C1-C3 alkylthio-,
(I) C1-C5 alkyl, (m) C4-C7 cyclic amino, (n) C4-C7 cycloalkylamino, (o) C1-C5 alkenyloxy,
(P) C3-C7 cycloalkenyl; wherein R16 is (a) aryl,
(b) amino,
(c) mono- or di- C1-C3 alkylamino,
(d) hydroxy,
(e) C3-C7 cycloalkyl,
(f) C4-C7 cyclic amino, or
(g) C1-C3 alkanoyloxy; wherein R 17 is
(a) -Het,
(b) C1-C5alkenyl,
(c) C3-C7 cycloalkenyl,
(d) C1-C3 alkoxy,
(e) mercapto,
(f) C1-C3alkylthio,
(g) -COOH,
(h) -CO-O-C1-C6 alkyl,
(i) -CO-O-CH2-(C1-C3alkyl)-N(C1-C3 alkyl)2,
(j) -CO-NR22R26,
(k) tri-C1-C3 alkylamino,
(l) guanidyl,
(m) cyano,
(n) N-cyanoguanidyl,
(o) (hydroxy C2 -C4 alkyl) amino,
(P) di-(hydroxy C2-C4 alkyl) amino, or
(q) cyanoamino; wherein R18 is
(a) amino,
(b) mono-, or di- C1-C3 alkylamino,
(c) C4-C7 cyclic amino, or
(d) C4-C7 cycloalkylamino; wherein R19 is
(a) aryl,
(b) -Het,
(c) tri-C1-C3 alkylamino,
(d) C3-C7 cycloalkyl,
(e) C1-C5 alkenyl,
(f) C3-C7 cycloalkenyl,
(g) hydroxy, (h) C1-C3 alkoxy,
(i) C1- C3 alkanoyloxy,
(j) mercapto,
(k) C1-C3 alkylthio,
(i) -COOH,
(m) -CO-O-C1-C6 alkyl,
(n) -CO-O-CH2-(C1-C3alkyl)-N(C1-C3alkyl)2,
(o) -CO-NR22R26,
(P) guanidyl,
(q ) cyano,
(r) N -cyanoguanidyl,
(s) cyano amino,
(t) (hydroxy C2-C4 alkyl ) amino ,
(u) di-(hydroxy C2-C4 alkyl) amino; or
(v) -SO3H; wherein R20 is
(a) hydrogen,
(b) C1-C5 alkyl, or
(c) aryl-C1-C5 alkyl; wherein R21 is
(a) -NH2, or
(b) -OH; wherein R2 2 is
(a) hydrogen, or
(b) C1-C3 alkyl; wherein R23 is
(a) -(CH2)n-OH,
(b) -(CH2)n-NH2,
(c) aryl, or
(d) C1-C3 alkyl; wherein R2 4 is
(a) -R1,
(b) -(CH2 )n-OH, or
(c) -(CH2 )n-NH2; wherein R2 5 is -(CH2)n-R13 ; wherein R2 6 is
(a) hydrogen,
(b) C1-C3 alkyl, or (c) phenyl-C1-C3 alkyl; wherein i is one to three, inclusive; wherein m is one or two; wherein for each occurrence n is independently an integer of zero to five, inclusive; wherein p is zero to 2 inclusive; wherein q is 1 to 5, inclusive; wherein Q is
(a) -CH2-, (b) -CH(OH)-,
(c) -O-, or
(d) -S-; and wherein M is
(a) -CO-, or (b) -CH2-; wherein aryl is phenyl or naphthyl substituted by zero to 3 of the following:
(a) C1-C3 alkyl,
(b) hydroxy, (c) C1-C3 alkoxy,
(d) halo,
(e) amino,
(f) mono- or di-C1-C3 alkylamino,
(g) -CHO, (h) -COOH,
(i) COOR26,
(j) CONHR26,
(k) nitro,
(I) mercapto , (m) C1 -C3 alkylthio ,
(n) C1 -C3 alkylsulf inyl ,
(o) C1 -C3 alkylsulf onyl ,
(p) C1 -C3 alkylsulf onyl-N(R4 ) -
(q) SO3 H, (r) SO2NH2 ,
(s) -CN , or
(t) -CH2NH2 ; wherein -Het is a 5- or 6-membered saturated or unsaturated ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring, which heterocyclic moiety is substituted with zero to 3 of the following:
(i) C1-C6 alkyl, (ii) hydroxy, (iii) trifluoromethyl, (iv) C1-C4 alkoxy,
(v) halo, (vi) aryl, (vii) aryl C1-C4 alkyl-, (viii) amino, and (ix) mono- or di-C1-C4 alkylamino; with the overall provisos that
(1) X is R6-(CH2)i-C(O)- only when A6, B7 and Cs are absent;
(2) R18 or R19 is hydroxy, mercapto, or amino, or a monosubstituted nitrogen containing group bonded through the nitrogen only when n is not one;
(3) R12 is -(CH2)n-R13 and n is zero and both R13 and R15 are oxygen-, nitrogen-, or sulfur-containing substituents bonded through the hetero atom, only when the hetero atom is not also bonded to hydrogen; (4) R25 is -(CH2)n-R13 and n is zero only when R13 is other than a primary or secondary nitrogen-containing group, hydroxy or mercapto group or when R4 of -N(R4)R14 is other than hydrogen; and
(5) R17 or R19 is -COOH only when n for that moiety is other than zero; and or a carboxy-, amino-, or other reactive group-protected form or a pharmaceutically acceptable acid addition salt thereof.
2. A compound of claim 1, wherein A, B, H, and I are absent, and E10 F11 is XL6 .
3. Boc-((S-phenyl)-DL-Cys)-His-Leu¥[CH(OH)CH2]Val-Ile-AMP or N-[4- [[N-[N-(1-L-arginyl-L-prolyl)-L-phenylalanyl]-L-histidyl]amino]-3- hydroxy-6-methyl-l-oxoheptyl]-L-isoleucine, tris(trifluoroacetate) (salt), a compound of claim 2.
4. 3-(Phenylthio)propionyl-His-Leu¥[CH(OH)CH2]Val-Ile-AMP, or N-(2- hydroxy-5-methyl-1-(2-methylpropyl)-4-(((2-methyl-1-(((2-pyridinyl- methyl) amino) carbonyl)butyl) amino) carbonyl) hexyl)-α-((1-oxo-3- (phenylthio)propyl)amino)-1H-imidazole-4-propanamide, a compound of claim 2.
5. (Phenylthio)acetyl-His-Leu¥[CH(OH)CH2]Val-Ile-AMP, a compound of claim 2.
EP19860906653 1985-11-15 1986-10-21 Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties Withdrawn EP0245361A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79845985A 1985-11-15 1985-11-15
US798459 1991-11-26

Publications (1)

Publication Number Publication Date
EP0245361A1 true EP0245361A1 (en) 1987-11-19

Family

ID=25173460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860906653 Withdrawn EP0245361A1 (en) 1985-11-15 1986-10-21 Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties

Country Status (3)

Country Link
EP (1) EP0245361A1 (en)
JP (1) JPS63501364A (en)
WO (1) WO1987002986A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268374A (en) * 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) * 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
US5212157A (en) * 1989-06-06 1993-05-18 Bio-Mega, Inc. Enzyme inhibitors
US5126326A (en) * 1989-06-06 1992-06-30 Bio-Mega, Inc. Enzyme inhibiting peptide derivatives
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
TW217410B (en) * 1992-04-01 1993-12-11 Ciba Geigy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU537592B2 (en) * 1979-04-02 1984-07-05 E.R. Squibb & Sons, Inc. Mercaptoacyldipeptides
EP0114993B1 (en) * 1982-12-27 1990-05-16 Merck & Co. Inc. Renin inhibitory tripeptides
AU573735B2 (en) * 1983-02-07 1988-06-23 Aktiebolaget Hassle Peptide analogue enzyme inhibitors
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
US4663310A (en) * 1984-04-04 1987-05-05 Merck & Co., Inc. Renin inhibitors containing 2-substituted statine
DK356085A (en) * 1984-08-06 1986-02-07 Upjohn Co PURE INHIBITION OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8702986A1 *

Also Published As

Publication number Publication date
WO1987002986A1 (en) 1987-05-21
JPS63501364A (en) 1988-05-26

Similar Documents

Publication Publication Date Title
US4894437A (en) Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US5132400A (en) Peptides containing a (1-amino-2-hydroxy-2-heterocyclic)ethyl moiety
EP0189203A2 (en) Peptidylaminodiols
EP0202577A2 (en) N(Acyldipeptidyl)-aminoglycols
EP0299963B1 (en) Renin inhibitors having a lactam pseudo dipeptide
CA2005340A1 (en) Retroviral protease inhibitors
EP0483271B1 (en) Peptides containing diamino-glycols as transition-state mimics
EP0245361A1 (en) Novel renin inhibiting polypeptide analogs containing s-aryl-d- or l- or dl-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
WO1989004833A1 (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
WO1989010920A1 (en) Renin inhibitory peptides containing a substituted phenoxyacetyle group
US4864017A (en) Novel renin inhibiting peptides having a dihyroxyethylene isostere transition state insert
US5049548A (en) Renin-inhibitory di-, tri-, and tetrapeptides
EP0312157A2 (en) Tetrapeptide renin inhibitors having a novel c-terminal amino acid
CA1309555C (en) Inhibiting peptides having a dihydroxyethylene isostere transitionstate insert
WO1989001488A1 (en) Renin inhibiting peptides with nonpeptide linkages
US5114925A (en) Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
EP0355065A1 (en) Renin inhibitory peptides containing suleptanic acid or derivatives thereof
AU617740B2 (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
AU617740C (en) Renin inhibiting peptides that contain amino and hydroxy dicarboxylic acids
WO1988007053A1 (en) Renin inhibitors containing a cyclopropyl amino acid and/or a cycloalkyl transition-state analogue
WO1991007430A1 (en) Peptides containing cyclic tripeptides
AU2541588A (en) Renin inhibitors containing a (1-amino-2-hydroxy-2- heterocyclic)ethyl moiety
WO1990003389A1 (en) Renin inhibitory peptides containing maleamide substituents
JPH02501140A (en) Renin-inhibitory peptides with epoxide or glycol groups
JPH02504143A (en) Renin inhibitory peptide containing malic acid derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870806

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19900315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920622

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TEN BRINK, RUTH, E.